Isoquinoline alkaloid supplement (AMPK activator)

Berberine

Berberine has no human elimination half-life in the sources cited here, so the app's 5 hours is a modelled figure, and a 2021 trial paper calls its oral bioavailability "extremely low (<1%)" against the app's 1%.1

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Berberine after one dose: 50% at ~5 h, 25% at 10 h, 12.5% at 15 h.

Drawn from the half-life in the app's model, ~5 h. The model's figures

Berberine is described by Dumitru and colleagues (Pharmaceuticals, 2026) as "an isoquinoline alkaloid present in Berberis spp., Coptis chinensis and Hydrastis canadensis".2 The app files it as a supplement in the subcategory AMPK activator, with oral as its only route, and lists berberine hydrochloride and dihydroberberine among its synonyms. Guo and colleagues (European Journal of Clinical Pharmacology, 2012) write that it "has been used for about 1,000 years to treat diarrhea" and is "widely used in Oriental countries for diabetes, hypercholesterolemia, and other medical conditions".3 The app grades the evidence as moderate and its notes open with cautions about interactions with prescription medicines, glucose-lowering drugs, pregnancy, breastfeeding and newborns. Two reviews describe the trials they pooled as mostly run in China.10,11

In Yin and colleagues' 2008 trial paper, the mechanism statements come from animal and cell work that the authors cite, not from measurements in participants, while Guo and colleagues and Wu and colleagues offer CYP-based explanations of interaction findings measured in people, which they word as possible or most likely.4,3,7 Yin and colleagues, discussing their 2008 trial, cite work in hamsters with hyperlipidemia in which berberine "increased LDL receptor mRNA as well as protein in the liver".4 The same discussion says berberine "was reported to inhibit lipid synthesis in human hepatocytes through activation of AMPK", which is a cell finding, not a result in trial participants.4 On drug handling, Guo and colleagues suggest that the CYP2D6 effect "may be caused by substrate competition", since CYP2D6 metabolises berberine.3 Dumitru and colleagues add that "Local inhibition of CYP3A4 and P-glycoprotein in the intestinal wall can markedly increase the absorbed fraction of the victim drug", a mechanism proposed in their narrative review.2

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~5 h
Bioavailability
1%
Typical dose
500–1500 mg/day
Route
Oral
Time to peak
~4 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~5 h (one-compartment model)No human elimination half-life for berberine appears in the sources cited here; the app's notes call the 5-hour half-life, 4-hour peak and 1% bioavailability modelled, not measured1
Bioavailability1%"Extremely low (<1%) in both animal and human models" in a 2021 trial paper; "below 1% in rats and below a few percent in humans" in a 2026 review1,2
Time to peak~4 h4.55 ± 0.29 h for free berberine and 3.59 ± 0.34 h for total berberine after berberine chloride 500 mg in 12 healthy volunteers (mean ± S.E.M.) in a 2021 study by authors who state they are Indena employees; plasma was sampled from 0 to 120 minutes after the fourth dose in a 2021 crossover pilot6,1
Peak concentrationNot in the app0.4 ± 0.17 ng/mL after a 500 mg berberine dose (fourth dose, healthy men, n = 5); 76.70 ± 14.04 pg/mL for total berberine and 69.95 ± 14.54 pg/mL for free berberine after berberine chloride 500 mg in 12 healthy volunteers (mean ± S.E.M.); the 2026 review states peak plasma concentration after usual doses is "on the order of nanograms per milliliter"1,6,2
MetaboliteNot in the appBerberrubine was "the main metabolite" in healthy volunteers after a single dose and in hypercholesterolemic patients on chronic administration5

Spinozzi and colleagues (Journal of Natural Products, 2014) say berberine's pharmacokinetics "remain unclear, and conflicting data have been reported".5 A study of a phytosome formulation (Petrangolini and colleagues, 2021, by authors who state they are Indena employees) reported that "24 hours after administration of BBR-PP, berberine is still detectable at plasma level"; this concerns that formulation, not unformulated berberine.6

4

Human studies

The table lists the trials, reviews and one registry entry read for this compound.

Table 4.1Human studies9 rows
Study and yearDesignPeopleDose and lengthMain result
Yin and colleagues, Metabolism, 20084Pilot; A: berberine against metformin; B: berberine added to existing treatment; hospital and NIH funding84 adults with type 2 diabetes (A 36, B 48)500 mg three times daily, 13 weeksStudy A: HbA1c 9.5% ± 0.5% to 7.5% ± 0.4%, similar to metformin; study B: 8.1% ± 0.2% to 7.3% ± 0.3%; gastrointestinal events in 20 (34.5%)4
Guo and colleagues, Eur J Clin Pharmacol, 20123Randomised two-phase crossover against placebo, 4-week washout; NIH and Chinese grants18 healthy Chinese men entered, 17 completed300 mg three times daily for 14 days, then probe drugsCYP2D6, CYP2C9 and CYP3A4 activity decreased; CYP1A2 and CYP2C19 probes showed no significant change3
Wu and colleagues, Eur J Clin Pharmacol, 20057Randomised controlled trial plus a six-patient pharmacokinetic study; Wuhan General Hospital104 renal-transplant recipients (52 and 52); 6 in the pharmacokinetic part0.2 g three times daily, 3 months (12 days in the pharmacokinetic part)Ciclosporin trough concentration rose 88.9% with berberine and 64.5% without; final values 29.3% higher with berberine7
Zhao and colleagues, Nutrients, 20218Randomised, double-blind, placebo-controlled; Hong Kong government fund84 Chinese men with hyperlipidemia; 80 completed500 mg twice daily, 12 weeksTotal cholesterol -0.39 mmol/L (95% CI -0.70 to -0.08) and HDL cholesterol -0.07 mmol/L (-0.13 to -0.01) against placebo; triglycerides, blood pressure, BMI and waist-hip ratio did not differ8
Moon and colleagues, Nutrients, 20211Randomised, double-blind, placebo-controlled crossover pilot; funded by NNB Nutrition5 healthy menBerberine 500 mg, dihydroberberine 100 mg or 200 mg, or placebo; four dosesPlasma berberine Cmax 0.4 ± 0.17 ng/mL after berberine 500 mg and 3.76 ± 1.4 ng/mL after dihydroberberine 100 mg; no significant change in glucose or insulin1
BRAVO registry entry, NCT056479159Multicentre, randomised, double-blinded registered trial; sponsor China National Center for Cardiovascular Diseases337 enrolled, people with obesity and non-alcoholic fatty liver diseaseBerberine hydrochloride 500 mg twice a day for 6 months, against placebo, after a 4-week run-in with berberineStatus completed; primary outcomes are visceral and liver fat by CT; the registry entry as read contains no posted results but lists a derived publication, Lei L et al., JAMA Netw Open 20269
Guo and colleagues, Oxid Med Cell Longev, 202110Systematic review and meta-analysis of randomised trials; Natural Science Foundation of China grant46 trials in people with type 2 diabetesBerberine alone or with standard therapy against controlHbA1c MD -0.73 (95% CI -0.97 to -0.51), FPG MD -0.86 (-1.10 to -0.62), triglycerides MD -0.5 (-0.61 to -0.39)10
Blais and colleagues, Drugs, 202311Meta-analysis of randomised placebo-controlled trials in adults18 studies, 1788 participants, 15 in mainland China or Hong KongDurations 4 to 24 weeksLDL cholesterol -0.46 mmol/L (95% CI -0.62 to -0.30; 14 studies, n = 1447); among 16 studies that reported adverse events, no serious adverse events were reported for berberine, and gastrointestinal events in 12 studies tended to be more frequent with berberine than placebo (2-23% vs 2-15%)11
Liu and colleagues, Front Pharmacol, 202512Meta-analysis of randomised placebo-controlled trials; Chinese medicine research funds12 included studies, people with metabolic syndrome componentsBerberine against placeboTriglycerides WMD -0.367 mmol/L; fasting glucose WMD -0.515 mmol/L; BMI WMD -0.435 kg/m2; no significant effect on HDL cholesterol or blood pressure12

Deeper analysis: Yin and colleagues, type 2 diabetes pilot (2008)

Yin and colleagues reported the trial in Metabolism in 2008 as a pilot study in two parts, run at the diabetes outpatient department of Xinhua Hospital.4 Study A randomised 36 newly diagnosed adults to berberine or metformin 0.5 g three times daily for 3 months; study B added berberine 500 mg three times daily to existing treatment in 48 adults whose diabetes was poorly controlled.4 In study A, the authors write that "The hypoglycemic effect of berberine was similar to that of metformin", with HbA1c falling from 9.5% ± 0.5% to 7.5% ± 0.4% on berberine and fasting glucose from 10.6 ± 0.9 mmol/L to 6.9 ± 0.5 mmol/L.4 Secondary and null results in study A: triglycerides and total cholesterol were significantly lower than with metformin at week 13, while for HDL-C and LDL-C "no significant differences between week 1 and week 13 were observed in the berberine group".4 Study B reported HbA1c "from 8.1% ± 0.2% to 7.3% ± 0.3%", a comparison within the same patients over time, with no comparison group described.4 Three patients on berberine and two on metformin withdrew in study A because of treatment failure, and five participants were excluded from study B before week 13.4 Gastrointestinal events occurred in 34.5% across both parts, with diarrhea in 6 (10.3%), constipation in 4 (6.9%), flatulence in 11 (19.0%) and abdominal pain in 2 (3.4%); berberine was cut from 0.5 g to 0.3 g three times daily in 14 (24.1%).4 Of those 14, ten were taking metformin or acarbose with berberine and the rest insulin with berberine, and the authors report that none of the patients had severe gastrointestinal adverse events when berberine was used alone.4 The authors report that "No significant changes of plasma ALT, γ-GT and creatinine were observed during the 13 weeks of berberine treatment".4 On limits, they call it a pilot, state that "The efficacy of berberine needs to be tested in a much larger population", and call for studies "in other ethnic groups".4 Funding: "Financial support for this study was provided by Xinhua Hospital", with partial support from an NIH grant to J Ye; the text read gives no author tie to a berberine maker.4

Deeper analysis: Guo and colleagues, cytochrome P450 study (2012)

Guo and colleagues reported a two-phase randomised crossover study in healthy men in the European Journal of Clinical Pharmacology in 2012.3 Eighteen healthy Chinese men entered, 17 completed, and one quit "because of a schedule conflict".3 They took placebo or berberine capsules at 300 mg three times daily for 14 days, with a 4-week washout, and probe drugs for five enzymes were then given.3 The urinary dextromethorphan/dextrorphan ratio, a CYP2D6 marker, "increased ninefold", and the losartan/E-3174 ratio, a CYP2C9 marker, "doubled".3 For midazolam, a CYP3A4 probe, AUC0–∞ rose from 45.08 to 65.18 ng·h/ml, a ratio of 140% (90% CI 117% to 168%), and the authors state that "CYP3A4 activity was also inhibited".3 Null results: "There were no statistically significant differences in the pharmacokinetic parameters of the other probe drugs", meaning the caffeine (CYP1A2) and omeprazole (CYP2C19) probes.3 The authors note that caffeine exposure changed in a direction short of significance and attribute this to "the small sample size of the study", and that "The individual variability was relatively large", which they suggest "might be genotype-dependent".3 They ask for "Further studies in larger populations and multiple dosage administrations".3 Funding came from the US National Institutes of Health and Chinese national and provincial grants, and the authors "report no conflict of interest".3

Deeper analysis: Wu and colleagues, ciclosporin in transplant recipients (2005)

Wu and colleagues, from the Department of Clinical Pharmacology, Wuhan General Hospital, reported the study in the European Journal of Clinical Pharmacology in 2005.7 The randomised trial gave ciclosporin with 0.2 g berberine three times daily for 3 months to 52 renal-transplant recipients, against 52 who received ciclosporin alone.7 Trough concentration rose 88.9% from baseline with berberine and 64.5% without, and at the end the berberine group was "still 29.3% and 27.8%, respectively, higher" for concentration and concentration/dose ratio.7 In six patients given berberine for 12 days, mean ciclosporin AUC "was increased by 34.5%".7 The authors report "No significant effects on liver or renal functions" and suggest the mechanism is "inhibition of CYP3A4 by BBR in the liver and/or small intestine".7 The journal record read for this study gives no funding statement, author limitations or adverse event data beyond these points.

Deeper analysis: Zhao and colleagues, men with hyperlipidemia (2021)

Zhao and colleagues reported a randomised, double-blind, placebo-controlled parallel trial in Hong Kong in Nutrients in 2021.8 They enrolled 84 Chinese men with hyperlipidemia, 42 per arm, who took berberine 500 mg twice a day or placebo for 12 weeks; 80 completed.8 Two men in each group withdrew "due to not feeling well" or other personal reasons.8 At 12 weeks the berberine group had larger reductions in total cholesterol (-0.39 mmol/L, 95% CI -0.70 to -0.08) and HDL cholesterol (-0.07 mmol/L, 95% CI -0.13 to -0.01).8 In a model using both the 8-week and 12-week data, the authors report that berberine "lowered total cholesterol and possibly low-density lipoprotein-cholesterol (LDL-c), and possibly increased testosterone".8 Null results: the authors report that "Changes in triglycerides, thromboxane A2, blood pressure, body mass index and waist-hip ratio after the intervention did not differ between the berberine and placebo groups".8 The authors say the HDL reduction "might have occurred by chance" because it was not seen when both time points were combined, and report "No serious adverse event".8 Among their stated limitations are that "the sample size of this study was relatively small" and that "findings in Chinese might not apply to other populations".8 The study was supported by the Health and Medical Research Fund of the Hong Kong government, and the authors declare no conflict of interest.8

Deeper analysis: Moon and colleagues, berberine and dihydroberberine absorption (2021)

Moon and colleagues reported a randomised, double-blind, placebo-controlled crossover pilot in Nutrients in 2021.1 Five healthy men each took placebo, berberine 500 mg, dihydroberberine 100 mg and dihydroberberine 200 mg, with three doses the day before and a fourth on the test morning; blood was drawn from 0 to 120 minutes.1 Peak plasma berberine was 0.4 ± 0.17 ng/mL after berberine 500 mg and 3.76 ± 1.4 ng/mL after dihydroberberine 100 mg, and AUC was 42.3 ± 17.6 against 284.4 ± 115.9 ng/mL × 120 min.1 The 200 mg dihydroberberine peak (12.0 ± 10.1 ng/mL) "tended (p = 0.06) to be different than B500".1 Null result: "No significant differences in the levels of glucose (p = 0.97) and insulin (p = 0.24) were observed", which the authors attribute to "the short duration of supplementation and insulin responsive nature of study participants".1 Eleven adverse events were reported in total, six on 100 mg dihydroberberine, three on placebo, one on 200 mg dihydroberberine and one on berberine 500 mg, and "All but one" were rated mild by participants and one moderate.1 The authors name sample size as "A key limitation", and say that whether higher plasma berberine "translate beyond one day" or into efficacy "cannot be determined from this project".1 Funding and ties: "This study was funded by NNB Nutrition", the dihydroberberine "was manufactured by NNB Nutrition (Nanjing, China)", and one author "serves as a paid advisor for NNB Nutrition", with a conflict-of-interest management plan filed with the university board.1

Systematic reviews

Guo and colleagues (Oxidative Medicine and Cellular Longevity, 2021) assessed 46 trials in type 2 diabetes and report mean differences of -0.73 for HbA1c (95% CI -0.97 to -0.51), -0.86 for fasting plasma glucose (-1.10 to -0.62) and -0.5 for triglycerides (-0.61 to -0.39).10 Their stated limitations include that "most of the trials were conducted among Chinese patients", that "excessive statistical heterogeneity appeared in some comparisons" with a source that "could not be determined", and that "Many of these studies did not report the methods of blinding and allocation concealment".10 On safety they state the treatment "did not increase the risk of serious adverse events when the routine dosage ranged from 0.6 g to 1.5 g", and they declare no conflict of interest and funding from the Natural Science Foundation of China.10 Blais and colleagues (Drugs, 2023) pooled 18 placebo-controlled trials (n = 1788) and report LDL cholesterol lower by 0.46 mmol/L, total cholesterol by 0.48 mmol/L and triglycerides by 0.34 mmol/L, with HDL cholesterol higher by 0.06 mmol/L (95% CI 0.00 to 0.11) overall and different in women and men.11 Its authors conclude "Berberine produces small reductions in LDL cholesterol, triglycerides, and apolipoprotein B" and that "Large-scale trials that consider sex disparity and assess clinical outcomes are required"; the record read does not state funding.11 Liu and colleagues (Frontiers in Pharmacology, 2025) pooled placebo-controlled trials and report triglycerides lower by a WMD of -0.367 mmol/L (95% CI -0.560 to -0.175) and fasting plasma glucose by -0.515 mmol/L (95% CI -0.847 to -0.183), with no significant effect on HDL cholesterol or blood pressure; BMI, listed among the secondary indicators, was lower by -0.435 kg/m2 (95% CI -0.856 to -0.013), and they say "more high-quality, rigorously designed randomized controlled trials are needed".12

5

Doses reported in studies and on labels

No product label with berberine dosing was fetched, so the table lists doses used in studies. The app lists a typical range of 500 to 1500 mg/day by mouth.

Table 5.1Doses reported in studies and on labels6 rows
StudyDose, route and scheduleLength and peopleReference
Yin 2008Berberine 500 mg three times daily by mouth; 300 mg three times daily after gastrointestinal effects in 14 (24.1%)13 weeks; 84 adults with type 2 diabetes4
Guo 2012Berberine 300 mg three times daily by mouth, against placebo14 days; 17 healthy men completed3
Wu 2005Berberine 0.2 g three times daily by mouth with ciclosporin3 months in 52 transplant recipients; 12 days in 67
Zhao 2021Berberine 500 mg twice daily by mouth, against placebo12 weeks; 84 men with hyperlipidemia8
Moon 2021Berberine 500 mg, or dihydroberberine 100 mg or 200 mg, by mouth, against placebo; four dosesDay before and test morning; 5 healthy men1
BRAVO registry entryBerberine hydrochloride 500 mg twice a day by mouth with lifestyle intervention, against placebo6 months after a 4-week run-in; 337 enrolled9

In Yin and colleagues' trial, 20 (34.5%) patients "suffered from transient gastrointestinal adverse effects", including flatulence in 19.0%, diarrhea in 10.3%, constipation in 6.9% and abdominal pain in 3.4%.4 Blais and colleagues report gastrointestinal adverse events in 12 studies that "tended to be more frequent" with berberine than placebo (2-23% against 2-15%), and, among 16 studies that reported adverse events, no serious adverse events for berberine.11 Guo and colleagues, pooling 15 type 2 diabetes trials that reported gastrointestinal events, found that berberine "did not have more gastrointestinal AEs as compared to the control group" (RR = 0.81, 95% CI 0.46 to 1.14), and total adverse events were lower with berberine (RR = 0.70, 95% CI 0.57 to 0.87, 17 trials).10 Liu and colleagues report that "no significant difference was observed between berberine and placebo" for safety, and note that two of the 12 included studies lacked safety data.12 Dumitru and colleagues note that berberine's "intrinsic hypoglycemic effect adds to that of antidiabetic agents, such as sulfonylureas and insulin, increasing the risk of hypoglycemia".2 The app's notes describe gastrointestinal upset as common and dose-related. Linn and colleagues (Phytotherapy Research, 2012) report that in 20 patients with chronic cytopenic haematological conditions whose herbal mixtures contained berberine-containing herbs, "no organ toxicity or electrolyte imbalance" occurred, while in three patients with thalassemia intermedia "transient elevation in serum bilirubin level was observed".13

7

Bloodwork and markers

The app lists HbA1c, fasting glucose, lipids and liver enzymes (ALT, AST) as markers to monitor. In Yin and colleagues' trial, HbA1c, fasting and postprandial glucose and lipids were the measured outcomes, and ALT, γ-GT and creatinine showed no significant change over 13 weeks.4 Zhao and colleagues measured total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, thromboxane A2 and testosterone, and report that "Berberine did not lower testosterone but instead may increase testosterone in men".8 Ciclosporin trough concentration was the marker followed in transplant recipients given berberine.7

8

Regulatory and anti-doping status

The 2026 WADA Prohibited List text contains no entry named berberine in a search of the full document.14 The same list prohibits a class of "Activators of the AMP-activated protein kinase (AMPK)" under S4.4.1, with BAM15, AICAR and MOTS-c given as examples; the sources read do not say whether berberine falls under that class.14 The app's notes say berberine is not WADA prohibited; the name search above does not settle that, because the list also names a class of AMPK activators.14 Linn and colleagues report that two berberine-containing herbs "have been banned in Singapore for the past three decades due to implication of berberine in aggravating jaundice and kernicterus in neonates with glucose-6-phosphate dehydrogenase deficiency", and that their review of the literature "found conflicting evidence of varying levels either supporting or refuting the allegation".13 No medicines-regulator assessment of berberine as a product was fetched for this compound.

No human elimination half-life for unformulated berberine appears in the sources cited here, so the app's 5-hour half-life rests on modelling, and the app's notes call its 4-hour peak modelled too; one 12-volunteer study reports Tmax of 4.55 h for free and 3.59 h for total berberine after berberine chloride 500 mg.1,6 The registered BRAVO trial in obesity and fatty liver is listed as completed, and its entry as read shows no posted results but cites a derived publication (Lei L et al., JAMA Netw Open 2026) whose content is not among the sources cited.9 The app's cautions on pregnancy, breastfeeding and newborns are not tested in the sources cited here; the Singapore ban rests on a newborn jaundice allegation that Linn and colleagues describe as having conflicting evidence.13

What is the half-life of berberine?

No human elimination half-life for berberine appears in the sources cited here, and the app lists about 5 hours as a modelled figure. Moon and colleagues sampled plasma only to 120 minutes after the fourth dose.1

Is berberine banned by WADA?

The 2026 WADA Prohibited List text contains no entry named berberine.14 The app's notes also say it is not WADA prohibited, while the list prohibits a class of AMPK activators with BAM15, AICAR and MOTS-c as examples.14

What is the bioavailability of berberine?

A 2021 trial paper states that oral berberine bioavailability is "extremely low (<1%)" in animal and human models, and the app lists 1%.1 A 2026 review estimates it at "below 1% in rats and below a few percent in humans".2

Does berberine affect other medicines?

In 17 healthy men who completed a crossover study, berberine 300 mg three times daily for 14 days decreased CYP2D6, CYP2C9 and CYP3A4 activities.3 In renal-transplant recipients, ciclosporin trough concentrations ended 29.3% higher with berberine than without.7

Does berberine lower HbA1c?

In a meta-analysis of 46 trials in type 2 diabetes, berberine alone or with standard therapy lowered HbA1c by a mean difference of -0.73 (95% CI -0.97 to -0.51) against control.10 The review's authors say most of the trials were in Chinese patients and many did not report blinding or allocation concealment methods.10

Does berberine lower LDL cholesterol?

In a meta-analysis of 18 placebo-controlled trials (n = 1788), berberine reduced LDL cholesterol by 0.46 mmol/L (95% CI 0.30 to 0.62) across 14 studies.11 Its authors describe these as "small reductions" and ask for large-scale trials with clinical outcomes.11

What are the side effects of berberine?

In Yin and colleagues' trial, 20 (34.5%) patients had gastrointestinal adverse events, and Guo and colleagues' meta-analysis names gastrointestinal responses as the main reported adverse events of berberine treatment.4,10 In a meta-analysis of placebo-controlled lipid trials, gastrointestinal events "tended to be more frequent" with berberine (2-23% against 2-15%) and, among 16 studies that reported adverse events, no serious adverse events were reported for berberine.11 A meta-analysis of metabolic syndrome components reported no significant difference between berberine and placebo for safety.12

Is dihydroberberine the same as berberine?

Dihydroberberine is a reduced form of berberine that the app lists as a synonym and describes in its notes as having limited data. In a pilot of five healthy men, plasma berberine peaked at 3.76 ± 1.4 ng/mL after dihydroberberine 100 mg and 0.4 ± 0.17 ng/mL after berberine 500 mg.1

12

References

  1. Moon JM, et al. Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. Nutrients 2021. Moon 2021
  2. Dumitru CN, et al. Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification, A Narrative Review. Pharmaceuticals (Basel) 2026. Dumitru 2026 review
  3. Guo Y, et al. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol 2012. Guo 2012
  4. Yin J, et al. Efficacy of Berberine in Patients with Type 2 Diabetes. Metabolism 2008. Yin 2008
  5. Spinozzi S, et al. Berberine and its metabolites: relationship between physicochemical properties and plasma levels after administration to human subjects. J Nat Prod 2014. Spinozzi 2014
  6. Petrangolini G, et al. Development of an Innovative Berberine Food-Grade Formulation with an Ameliorated Absorption: In Vitro Evidence Confirmed by Healthy Human Volunteers Pharmacokinetic Study. Evid Based Complement Alternat Med 2021. Petrangolini 2021
  7. Wu X, et al. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol 2005. Wu 2005
  8. Zhao JV, et al. Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial. Nutrients 2021. Zhao 2021
  9. ClinicalTrials.gov. NCT05647915: Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD (BRAVO). Registry entry, last update 2025-01-29. NCT05647915
  10. Guo J, et al. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxid Med Cell Longev 2021. Guo 2021 meta-analysis
  11. Blais JE, Huang X, Zhao JV. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs 2023. Blais 2023 meta-analysis
  12. Liu D, et al. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Front Pharmacol 2025. Liu 2025 meta-analysis
  13. Linn YC, et al. Berberine-induced haemolysis revisited: safety of Rhizoma coptidis and Cortex phellodendri in chronic haematological diseases. Phytother Res 2012. Linn 2012
  14. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list